BRPI0518173B8 - composições oftálmicas tópicas para tratamento de olho seco e seus usos - Google Patents

composições oftálmicas tópicas para tratamento de olho seco e seus usos

Info

Publication number
BRPI0518173B8
BRPI0518173B8 BRPI0518173A BRPI0518173A BRPI0518173B8 BR PI0518173 B8 BRPI0518173 B8 BR PI0518173B8 BR PI0518173 A BRPI0518173 A BR PI0518173A BR PI0518173 A BRPI0518173 A BR PI0518173A BR PI0518173 B8 BRPI0518173 B8 BR PI0518173B8
Authority
BR
Brazil
Prior art keywords
dry eye
ophthalmic compositions
eyes
treating dry
topical ophthalmic
Prior art date
Application number
BRPI0518173A
Other languages
English (en)
Inventor
Chang-Lin Joan-En
G Vehige Joseph
A Simmons Peter
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36218032&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0518173(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Priority to BR122019023144A priority Critical patent/BR122019023144B8/pt
Publication of BRPI0518173A publication Critical patent/BRPI0518173A/pt
Publication of BRPI0518173A8 publication Critical patent/BRPI0518173A8/pt
Publication of BRPI0518173B1 publication Critical patent/BRPI0518173B1/pt
Publication of BRPI0518173B8 publication Critical patent/BRPI0518173B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1732—Lectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

patente de invenção: composição oftálmica e usos. a presente invenção refere-se a composições oftálmicas incluindo componentes solutos compatíveis e/ou componentes polianlônícos que são utilizáveis no tratamento dos olhos, por exemplo, para aliviar a síndrome de olhos secos, para proteger os olhos contra insulto hipertônico e/ou efeitos adversos de espécies catiônicas nas superfícies oculares dos olhos e/ou para facilitar a recuperação de cirurgia no olho.
BRPI0518173A 2004-11-16 2005-11-14 composições oftálmicas tópicas para tratamento de olho seco e seus usos BRPI0518173B8 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122019023144A BR122019023144B8 (pt) 2004-11-16 2005-11-14 composições oftálmicas tópicas para tratamento de olho seco e seus usos

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/990,811 US8569367B2 (en) 2004-11-16 2004-11-16 Ophthalmic compositions and methods for treating eyes
PCT/US2005/041064 WO2006055454A2 (en) 2004-11-16 2005-11-14 Ophthalmic compositions and methods for treating eyes

Publications (4)

Publication Number Publication Date
BRPI0518173A BRPI0518173A (pt) 2008-11-04
BRPI0518173A8 BRPI0518173A8 (pt) 2018-01-23
BRPI0518173B1 BRPI0518173B1 (pt) 2020-05-19
BRPI0518173B8 true BRPI0518173B8 (pt) 2021-05-25

Family

ID=36218032

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0518173A BRPI0518173B8 (pt) 2004-11-16 2005-11-14 composições oftálmicas tópicas para tratamento de olho seco e seus usos
BR122019023144A BR122019023144B8 (pt) 2004-11-16 2005-11-14 composições oftálmicas tópicas para tratamento de olho seco e seus usos

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122019023144A BR122019023144B8 (pt) 2004-11-16 2005-11-14 composições oftálmicas tópicas para tratamento de olho seco e seus usos

Country Status (23)

Country Link
US (11) US8569367B2 (pt)
EP (4) EP3777836A1 (pt)
JP (1) JP5179880B2 (pt)
KR (1) KR101344602B1 (pt)
CN (1) CN101056618B (pt)
AR (1) AR052031A1 (pt)
AU (2) AU2005306721B2 (pt)
BR (2) BRPI0518173B8 (pt)
CA (1) CA2588044C (pt)
CY (2) CY1116545T1 (pt)
DK (3) DK1811959T4 (pt)
ES (3) ES2543974T3 (pt)
HU (2) HUE026575T2 (pt)
IL (1) IL182532A (pt)
NO (3) NO347855B1 (pt)
NZ (2) NZ597106A (pt)
PL (3) PL218364B1 (pt)
PT (2) PT1811959E (pt)
RU (1) RU2410081C2 (pt)
SI (2) SI1811959T2 (pt)
TW (1) TWI369996B (pt)
WO (1) WO2006055454A2 (pt)
ZA (1) ZA200702917B (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050147584A1 (en) * 2004-01-05 2005-07-07 Allergan, Inc. Compositions and methods comprising memantine and polyanionic polymers
US7220422B2 (en) 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
US8569367B2 (en) * 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
TWI393567B (zh) 2005-03-31 2013-04-21 Bausch & Lomb 治療乾眼之組合物及相關之製造方法及使用方法
TW200722109A (en) * 2005-03-31 2007-06-16 Bausch & Lomb Polysaccharide and polyol composition for treating dry eye and related methods of manufacture and methods of use
WO2007005421A2 (en) * 2005-07-01 2007-01-11 Bausch & Lomb Incorporated Long lasting alginate dry eye, related methods of manufacture and methods of use
AU2006265248B2 (en) * 2005-07-01 2011-12-15 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of L-carnitine or of alkanoyl L-carnitines for the preparation of a physiological supplement or medicament for ophthalmic use in the form of eye-drops
CN1939534B (zh) * 2005-09-27 2010-12-01 长春金赛药业股份有限公司 含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂
DE102005055275A1 (de) * 2005-11-17 2007-05-24 Ursapharm Arzneimittel Gmbh & Co. Kg Phosphatfreie pharmazeutische Zusammensetzung sowie deren Verwendung
US20080057022A1 (en) * 2006-08-30 2008-03-06 Erning Xia Ophthalmic Pharmaceutical Compositions and Uses Thereof
US8138156B2 (en) 2006-10-18 2012-03-20 Bausch & Lomb Incorporated Ophthalmic compositions containing diglycine
US20080095754A1 (en) * 2006-10-18 2008-04-24 Burke Susan E Ophthalmic compositions comprising diglycine
CN101534812B (zh) * 2006-12-11 2012-09-05 希格马托制药工业公司 L-卡尼汀制备用于治疗角膜疾病的滴眼剂形式药物的用途
DE102006060953A1 (de) * 2006-12-12 2008-08-07 Farco-Pharma Gmbh Pharmazeutische Zubereitung für die Behandlung entzündlicher Erkrankungen des Urogenitaltraktes
WO2008071528A1 (en) * 2006-12-14 2008-06-19 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of l-carnitine or of alkanoyl l-carnitines for the preparation of a physiological supplement or medicament for ophthalmic use in the form of eye drops
US20080148689A1 (en) * 2006-12-20 2008-06-26 Bausch & Lomb Incorporated Packaging solutions
US8629099B2 (en) 2008-03-25 2014-01-14 Bausch & Lomb Incorporated Ophthalmic compositions comprising a dipeptide
WO2010047927A1 (en) * 2008-10-20 2010-04-29 Allergan, Inc. Ophthalmic compositions useful for improving visual acuity
MX358504B (es) * 2009-06-05 2018-08-21 Allergan Inc Lagrimas artificiales y usos terapeuticos.
ITMI20100319A1 (it) * 2010-02-26 2011-08-27 Lo Li Pharma Srl Composizioni comprendenti mioinositolo e il loro uso nel trattamento delle malattie respiratorie.
US9636355B2 (en) 2011-09-22 2017-05-02 Theo Holdings, Llc Hypertonic dextran solution and methods of treating and preventing recurrent corneal erosion
US8957048B2 (en) * 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
ES2797650T3 (es) 2011-12-07 2020-12-03 Allergan Inc Administración de lípido eficiente a película lagrimal humana usando un sistema de emulsión sensible a sal
EP2794550B1 (en) * 2011-12-23 2019-02-20 University of Western Sydney Ophthalmic formulation
US8324171B1 (en) 2012-02-06 2012-12-04 Bausch & Lomb Incorporated Ophthalmic compositions containing diglycine
US8664180B2 (en) 2012-02-06 2014-03-04 Bausch & Lomb Incorporated Ophthalmic compositions containing diglycine
US10085960B2 (en) 2012-03-30 2018-10-02 Brien Holden Vision Institute Methods and compositions for reducing ocular discomfort
PT2950783T (pt) * 2013-02-01 2019-08-21 Allergan Inc Lágrimas artificiais compreendendo hialuronato de sódio e carboximetilcelulose
CA2994222C (en) 2014-08-20 2020-09-08 Silk Technologies, Ltd. Fibroin-derived protein composition
JP6768653B2 (ja) 2014-11-25 2020-10-14 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 安定したオメガ−３眼科用組成物
ITUB20153104A1 (it) * 2015-08-13 2017-02-13 Sooft Italia S P A Contrada Molino 17 68333 Montegiorgio Fm Composizione ed uso di collirio a base di inositolo per migliorare l'accomodazione visiva dei pazienti
KR20180074674A (ko) 2015-10-23 2018-07-03 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 조직 내 레이저 유도된 콜라겐 가교결합
SG11201808804TA (en) 2016-04-08 2018-11-29 Univ Cornell A method to enhance wound healing using silk-derived protein
US11497403B2 (en) 2016-06-10 2022-11-15 The Trustees Of Columbia University In The City Of New York Devices, methods, and systems for detection of collagen tissue features
RU2623205C1 (ru) * 2016-07-13 2017-06-22 Станислав Анатольевич Кедик Офтальмологический гель таурина
US11242367B2 (en) 2016-08-12 2022-02-08 Silk Technologies, Ltd. Silk-derived protein for treating inflammation
US11666481B1 (en) 2017-12-01 2023-06-06 The Trustees Of Columbia University In The City Of New York Diagnosis and treatment of collagen-containing tissues
SG10201907137RA (en) * 2019-08-02 2021-03-30 Singapore Health Serv Pte Ltd Use of an osmolyte in manufacture of a medicament for treatment of ocular disorders
AU2020419590A1 (en) 2019-11-15 2022-06-30 Silk Technologies, Ltd. Stable formulations of silk-derived protein
CN111467349B (zh) * 2020-05-14 2021-06-01 华熙生物科技股份有限公司 人工泪液及其制备方法
WO2022189552A1 (en) * 2021-03-10 2022-09-15 Bausch + Lomb Ireland Limited Preservative-free contact lens treating solution
US12012238B2 (en) * 2021-05-26 2024-06-18 Bausch + Lomb Ireland Limited Packaging solutions
CA3223191A1 (en) * 2021-09-03 2023-03-09 University Of Utah Research Foundation Compositions and methods for diagnosing, detecting and treating eosinophil-related diseases
IT202300019488A1 (it) * 2023-09-21 2025-03-21 D&V Farma Soc A Responsabilita Limitata Composizioni, usi e metodi per il trattamento della sindrome dell’occhio secco o per promuovere la guarigione delle ferite corneali
WO2025175150A1 (en) * 2024-02-16 2025-08-21 Allergan, Inc. Enhanced artificial tear formulations

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1781701A (en) 1928-05-16 1930-11-18 Phillips Morris Godfrey Philip Machine for removing flags and other adhering leaf from the stalks of tobacco leaves
US3278447A (en) 1963-12-02 1966-10-11 Cloro Bac Products Inc Process for stabilizing chlorine dioxide solution
US4201706A (en) * 1978-09-22 1980-05-06 Burton, Parsons & Company, Inc. Treatment of corneal edema
DE3066859D1 (en) 1979-10-26 1984-04-12 Smith & Nephew Ass Autoclavable emulsions
EP0145710A1 (en) * 1983-05-25 1985-06-26 Alcon Laboratories, Inc. Ophthalmic solution
IT1198449B (it) * 1986-10-13 1988-12-21 F I D I Farmaceutici Italiani Esteri di alcoli polivalenti di acido ialuronico
JPS6436255A (en) * 1987-07-31 1989-02-07 Fujitsu Ltd Feeding circuit
US5192535A (en) * 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
IT1235153B (it) * 1988-11-15 1992-06-22 Sigma Tau Ind Farmaceuti Uso dell'acetil l-carnitina nel trattamento terapeutico della cataratta e composizioni farmaceutiche utili in tale trattamento
IT1224795B (it) 1988-12-01 1990-10-24 Sigma Tau Ind Farmaceuti Uso dell'acetil d-carnitina nel trattamento terapeutico del glaucoma e composizioni farmaceutiche utili in tale trattamento
US5221696A (en) * 1989-03-29 1993-06-22 Alcon Laboratories, Inc. Use of monoacyl phosphoglycerides to enhance the corneal penetration of ophthalmic drugs
DE436726T1 (de) 1989-08-03 1992-02-06 Eisai Co., Ltd., Tokio/Tokyo Verfahren zur photostabilisierung von augenspuelloesungen sowie photostabilisierte augenspuelloesung.
US5681555A (en) * 1991-04-22 1997-10-28 Gleich; Gerald J. Method for the treatment of bronchial asthma by parenteral administration of anionic polymers
DE4229494A1 (de) † 1992-09-04 1994-03-10 Basotherm Gmbh Arzneimittel zur topischen Anwendung am Auge zur Behandlung des erhöhten intraokularen Drucks
JP3431216B2 (ja) 1993-06-18 2003-07-28 千代田化工建設株式会社 触媒層支持構造
CN1160346A (zh) 1994-09-14 1997-09-24 大正制药株式会社 用于修复角膜损伤的滴眼液
US5980865A (en) * 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
US5847294A (en) * 1996-04-09 1998-12-08 Amherst Process Instruments, Inc. Apparatus for determining powder flowability
JPH1036255A (ja) * 1996-07-24 1998-02-10 Nikken Chem Co Ltd 眼圧降下用点眼剤
IT1288399B1 (it) 1996-12-03 1998-09-22 Sigma Tau Ind Farmaceuti Medicamento per il trattamento terapeutico della maculopatia legata all'eta', della maculopatia non legata all'eta' e per la profilassi
FI106923B (fi) 1997-01-03 2001-05-15 Cultor Ltd Finnsugar Bioproduc Trimetyyliglysiinin käyttö kehon limakalvojen hygieniaan ja hoitoon tarkoitetuissa valmisteissa
AR002194A1 (es) 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
US6770675B2 (en) * 1997-03-17 2004-08-03 Novartis Ag Compositions and methods for reducing ocular hypertension
EP1021204B1 (en) * 1997-09-26 2005-12-28 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US6274725B1 (en) 1998-06-02 2001-08-14 Isis Pharmaceuticals, Inc. Activators for oligonucleotide synthesis
IT1302307B1 (it) * 1998-09-01 2000-09-05 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil
RU2211027C2 (ru) * 1998-10-23 2003-08-27 Идеа Аг Способ конструирования, проверки и применения ассоциатов макромолекул и комплексных агрегатов с повышенной полезной нагрузкой и контролируемой степенью ассоциации/диссоциации
WO2000029030A1 (en) 1998-11-13 2000-05-25 Continental Projects Limited Complexes of hyaluronic acid/carnitines and pharmaceutical and cosmetic compositions
US6228392B1 (en) * 1999-04-29 2001-05-08 Gene Tools, Llc Osmotic delivery composition, solution, and method
KR100354606B1 (ko) 2000-02-01 2002-09-30 주식회사 중외제약 다목적 콘택트 렌즈 관리 용액 조성물
DK2153819T3 (da) * 2000-07-14 2012-12-03 Allergan Inc Anvendelse af en opløselighedsforbedrende bestanddel i en vandig sammensætning omfattende brimonidintartrat
CA2355814C (en) * 2000-09-14 2010-06-29 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Pharmaceutical composition for ophthalmic use
US8557868B2 (en) 2000-11-04 2013-10-15 Fxs Ventures, Llc Ophthalmic and contact lens solutions using low molecular weight amines
AU2720602A (en) 2000-11-08 2002-05-21 Bio Concept Lab Improved ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers
US20030069410A1 (en) 2001-06-14 2003-04-10 Isis Pharmaceuticals, Inc. Methods for preparing oligonucleotides having chiral phosphorothioate linkages
AR036122A1 (es) 2001-07-03 2004-08-11 Avecia Biotechnology Inc Un complejo de sal que comprende un n-alquilimidazol y una 1,1-dioxo-1,2-dihidro-1l6-benzo [d]-isotiazol-3-ona y un metodo para sintetizar oligonucleotidos utilizando la quimica de fosforamidita
US6936589B2 (en) 2001-09-28 2005-08-30 Albert T. Naito Parenteral delivery systems
US7045121B2 (en) * 2001-12-14 2006-05-16 Allergan, Inc. Ophthalmic compositions for lubricating eyes and methods for making and using same
US6858614B2 (en) * 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenolic guanidine sodium channel blockers
RU2216346C1 (ru) * 2002-06-10 2003-11-20 Семенова Наталья Викторовна Средство и способ для биогенной стимуляции организма
AU2003259145A1 (en) 2002-07-17 2004-02-02 Spencer P. Thornton Treatment for dry eye syndrome
EP1551399A4 (en) * 2002-09-30 2011-01-05 Mark A Babizhayev METHOD FOR THE TOPICAL TREATMENT OF EYE DISEASES AND COMPOSITION AND DEVICE FOR THIS TREATMENT
ITRM20020492A1 (it) 2002-10-01 2004-04-02 Sigma Tau Ind Farmaceuti Uso della propionil l-carnitina per la preparazione di un medicamento per il trattamento del glaucoma.
US20040137079A1 (en) 2003-01-08 2004-07-15 Cook James N. Contact lens and eye drop rewetter compositions and methods
JPWO2004084877A1 (ja) 2003-03-26 2006-06-29 株式会社メニコン 眼科用組成物
US20050009836A1 (en) * 2003-06-26 2005-01-13 Laskar Paul A. Ophthalmic composition containing quinolones and method of use
US8569367B2 (en) * 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
BRPI0808410A2 (pt) 2007-02-28 2015-06-23 Aciex Therapeutics Inc Métodos e composições para normalizar secreções da glândula meibomiana
JP4929245B2 (ja) 2008-07-31 2012-05-09 株式会社ベッセル工業 工具類のグリップ
MX358504B (es) 2009-06-05 2018-08-21 Allergan Inc Lagrimas artificiales y usos terapeuticos.
US9907826B2 (en) * 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system

Also Published As

Publication number Publication date
NO20072170L (no) 2007-08-15
CY1116545T1 (el) 2017-03-15
WO2006055454A3 (en) 2006-08-03
PL1811959T3 (pl) 2015-11-30
US20140256675A1 (en) 2014-09-11
ES2550616T3 (es) 2015-11-11
US20130190398A1 (en) 2013-07-25
US10213405B2 (en) 2019-02-26
NZ583757A (en) 2011-11-25
BRPI0518173A (pt) 2008-11-04
CA2588044A1 (en) 2006-05-26
EP2422765B1 (en) 2015-04-29
US20140045773A1 (en) 2014-02-13
US9668997B2 (en) 2017-06-06
AU2012203398B2 (en) 2015-01-15
CA2588044C (en) 2014-05-27
SI1811959T2 (sl) 2022-10-28
EP1811959B1 (en) 2015-09-02
PL2422765T3 (pl) 2015-10-30
US20160256424A1 (en) 2016-09-08
HUE025116T2 (en) 2016-01-28
HK1107027A1 (zh) 2008-03-28
RU2410081C2 (ru) 2011-01-27
RU2007117637A (ru) 2008-12-27
TWI369996B (en) 2012-08-11
IL182532A0 (en) 2007-09-20
SI1811959T1 (sl) 2015-11-30
US20140045939A1 (en) 2014-02-13
EP2952178A1 (en) 2015-12-09
ES2550616T5 (es) 2022-09-29
AU2005306721A1 (en) 2006-05-26
US9254324B2 (en) 2016-02-09
BR122019023144B8 (pt) 2021-07-27
CN101056618B (zh) 2015-02-11
AU2005306721B2 (en) 2012-03-08
DK1811959T3 (en) 2015-11-23
EP3777836A1 (en) 2021-02-17
WO2006055454A2 (en) 2006-05-26
HK1218620A1 (en) 2017-03-03
DK2422765T3 (en) 2015-08-03
AR052031A1 (es) 2007-02-28
BRPI0518173A8 (pt) 2018-01-23
SI2422765T1 (sl) 2015-09-30
HUE026575T2 (en) 2016-06-28
TW200631605A (en) 2006-09-16
US8569370B2 (en) 2013-10-29
ES2842226T3 (es) 2021-07-13
JP2008520671A (ja) 2008-06-19
EP1811959B2 (en) 2022-06-15
NO347855B1 (no) 2024-04-22
IL182532A (en) 2013-10-31
EP1811959A2 (en) 2007-08-01
DK2952178T3 (da) 2020-12-07
US20230404961A1 (en) 2023-12-21
DK1811959T4 (da) 2022-06-27
US20210401789A1 (en) 2021-12-30
AU2012203398A1 (en) 2012-06-28
US20060106104A1 (en) 2006-05-18
PT1811959E (pt) 2015-11-10
PL218364B1 (pl) 2014-11-28
US20180021282A1 (en) 2018-01-25
US20190365692A1 (en) 2019-12-05
PT2422765E (pt) 2015-09-16
EP2422765A1 (en) 2012-02-29
EP2952178B1 (en) 2020-09-02
NO20240132A1 (no) 2007-08-15
JP5179880B2 (ja) 2013-04-10
US8729125B2 (en) 2014-05-20
NO346214B1 (no) 2022-04-25
US8569367B2 (en) 2013-10-29
BRPI0518173B1 (pt) 2020-05-19
KR101344602B1 (ko) 2013-12-31
US20250186385A1 (en) 2025-06-12
ZA200702917B (en) 2008-09-25
CY1116936T1 (el) 2017-04-05
KR20070084264A (ko) 2007-08-24
NO20220060A1 (pt) 2007-08-15
CN101056618A (zh) 2007-10-17
PL383268A1 (pl) 2008-02-18
BR122019023144B1 (pt) 2021-02-09
NZ597106A (en) 2013-06-28
ES2543974T3 (es) 2015-08-26

Similar Documents

Publication Publication Date Title
BRPI0518173B8 (pt) composições oftálmicas tópicas para tratamento de olho seco e seus usos
BRPI0520014A2 (pt) emulsões oftálmicas estáveis de óleo-em-água com hialuronato de sódio para alìvio de olho seco
MX2009012645A (es) Formulaciones y metodos para tratar el ojo seco.
BRPI0710085B8 (pt) composições oftálmicas e seus kits
WO2006091546A3 (en) Use of amniotic fluid (af) in treating ocular disease and injury
BR112014006607A2 (pt) composições e métodos para tratamento de presbiopia, hiperopia leve e astigmatismo irregular
WO2010042843A3 (en) Composition and method for treating dry eye syndrome
BRPI0406636A (pt) Lentes de contato e métodos e composições de gotas oftálmicas de reumidificação
MX2011013060A (es) Formulaciones oftalmicas, metodos de preparacion y metodos para utilizarlas.
BRPI0508540A (pt) composto, composição farmacêutica, e, uso de um composto
WO2013022846A3 (en) Flavonoid compounds
BR112012022074A2 (pt) composição compreendendo como ingredientes ativos l-carnitina em combinação com hidroxiquinurenina-o-beta-dl-glicosídeo, para a prevenção e/ou tratamento de patologias dos olhos devido à radiação ultravioleta
CY1111384T1 (el) Διαμορφωση των επιπεδων εκφρασης toy trpv
EP1935418A4 (en) Composition for relieving subjective symptoms of fatigue
WO2007067519A3 (en) The use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
BRPI0412131A (pt) métodos de tratamento de distúrbios oftálmicos, para evitar hemorragia retìnica, perda de acuidade visual, reduzir exsudatos duros e retardar progressão de dano retìnico
ATE428470T1 (de) Heilmittel zur behandlung von erkrankungen des sehnervs
BRPI0815599A2 (pt) Uso de uma fluoroquinolona, métodos para modular endoftalmite em um indivíduo e para tratar ou controlar uma infecção ocular ouo oftálmica que resulta em endoftalmite em um indivíduo, e, composição farmacêutica.
BR112017019824A2 (pt) compostos; composição farmacêutica; método para o tratamento profilático ou terapêutico da fibrose em um sujeito; usos de um composto; método para a prevenção, redução ou retardamento do acúmulo de gordura no fígado de um sujeito; método para a prevenção, redução ou retardamento da morte das células tubulares renais em um sujeito; e método para a restauração da arquitetura normal dos tecidos em um sujeito
WO2008145853A3 (fr) Utlisation d'un principe actif issu de l'amarante (amaranthus) pour preparer une composition destinee a activer l'energie cellulaire et a proteger la peau des dommages oxydatifs
MY145811A (en) Ophthalmic compositions and methods for treating eyes
MY176056A (en) Ophthalmic compositions and methods for treating eyes
WO2008145848A3 (fr) Composition pharmaceutique et/ou cosmetique contenant des peptides derives de l ' aconitase
WO2005080549A3 (de) Trioxacarcine und deren verwendung gegen infektionskrankheiten
TW200514554A (en) An ophthalmic composition for treating lacrimal fluid abnormal

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/05/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/11/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF